Cancer Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Cancer Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Market Overview:

The global cancer vaccines market size reached US$ 6.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 12.1 Billion by 2028, exhibiting a growth rate (CAGR) of 11.61% during 2023-2028.

Cancer is a malignant tumor caused by the uncontrollable growth of abnormal cells in the body. It can be treated through the use of various medications and vaccines. Between these, vaccines are broadly categorized into preventive and therapeutic. Preventive cancer vaccines are deployed for eliminating cancer caused by oncovirus and protecting from human papillomavirus (HPV), whereas therapeutic vaccines aid in stimulating the individual adaptive immune systems by using tumor antigens. At present, cancer vaccines are commercially available in varying types, such as antigen, dendritic cell, and anti-idiotype.

Cancer Vaccines Market Trends:
The increasing prevalence of cancer, especially due to the rising consumption of tobacco-based products and evolving lifestyles is currently driving the cancer vaccines market growth. In line with this, favorable initiatives undertaken by the government bodies of several nations for introducing novel cancer vaccines, along with extensive fundings in the field of viral recombinant cancer vaccines are further facilitating the widespread adoption of these vaccines in the healthcare sector. In line with this, the extensive utilization of United States Food and Drug Administration (US FDA) approved vaccines, including human papillomavirus vaccine (HPV) and hepatitis B vaccine (HBV) to reduce the risk of certain types of cancer, such as liver cancer, is contributing to the market growth. The market is also significantly driven by rapid technological advancements focusing on the development of effective and specific cancer treatments. Other factors, such as improving healthcare infrastructure, rising geriatric population, who are susceptible to various chronic ailments, including cancer, and growing consumer awareness regarding the symptoms and the available treatment options, are creating a positive outlook for the market further across the globe.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global cancer vaccines market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, technology, indication and end user.

Breakup by Type:

Preventive Cancer Vaccines
Therapeutic Cancer Vaccines

Breakup by Technology:

Dendritic Cells Cancer Vaccines
Recombinant Cancer Vaccines
Antigen/Adjuvant Cancer Vaccines
Viral Vector and DNA Cancer Vaccines
Whole-cell Cancer Vaccines

Breakup by Indication:

Cervical Cancer
Prostate Cancer
Others

Breakup by End User:

Pediatrics
Adults

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Anixa Biosciences Inc., Dendreon Pharmaceuticals LLC, Dynavax Technologies Corporation, GSK plc, Merck & Co. Inc., Moderna Inc., OSE Immunotherapeutics, Providence Therapeutics, Sanofi S.A., UbiVac Inc. and Vaccitech plc.

Key Questions Answered in This Report:
How has the global cancer vaccines market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global cancer vaccines market?
What are the key regional markets?
What is the breakup of the market based on the type?
What is the breakup of the market based on the technology?
What is the breakup of the market based on the indication?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global cancer vaccines market and who are the key players?
What is the degree of competition in the industry?